TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31766999

Group type: EXPERIMENTAL
Intervention: Audit and feedback-based intervention including centre-level feedback reports, webinars for facilitated conversations/coaching, and an online repository of curated transition resources.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 0
Study: 28553847

Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZE) 10 mg/day co-administered with atorvastatin 20 mg for 16 weeks
Number of subjects: 323

Group type: COMPARATOR
Intervention: Atorvastatin monotherapy (20 mg for 16 weeks)
Number of subjects: 323
Study: 26019992

Group type: EXPERIMENTAL
Intervention: Phonics training (8 weeks) followed by sight word training (8 weeks)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Sight word training (8 weeks) followed by phonics training (8 weeks)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Combined sight word and phonics training
Number of subjects: 41
Study: 24209977

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg) plus ledipasvir (90 mg) for 8 weeks (group 1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg) plus ledipasvir (90 mg) and ribavirin for 8 weeks (group 2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg) plus ledipasvir (90 mg) for 12 weeks (group 3)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg) plus ledipasvir (90 mg) for 12 weeks (group 4)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg) plus ledipasvir (90 mg) and ribavirin for 12 weeks (group 5)
Number of subjects: 100
Study: 22940818

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) at doses of 6,000 or 12,000 IU administered intravenously within 6 hours after successful percutaneous coronary intervention (PCI)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo administered intravenously within 6 hours after successful percutaneous coronary intervention (PCI)
Number of subjects: 600
Study: 19237568

Group type: EXPERIMENTAL
Intervention: MF59‐H5N1 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plain H5N1 vaccine
Number of subjects: 0
Study: 17890472

Group type: EXPERIMENTAL
Intervention: Inhaled human insulin
Number of subjects: 226

Group type: COMPARATOR
Intervention: Subcutaneous insulin
Number of subjects: 226
Study: 15890830

Group type: EXPERIMENTAL
Intervention: Unrestricted oral carbohydrate intake during labor
Number of subjects: 328

Group type: COMPARATOR
Intervention: Usual care (restricted to ice chips and water)
Number of subjects: 328
Study: 11300574

Group type: EXPERIMENTAL
Intervention: Independence-primed participants
Number of subjects: 4

Group type: COMPARATOR
Intervention: Interdependence-primed participants
Number of subjects: 4
Study: 9924225

Group type: EXPERIMENTAL
Intervention: Granisetron 20 micrograms kg‐1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms kg‐1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Granisetron 100 micrograms kg‐1
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 7524159

Group type: EXPERIMENTAL
Intervention: Paclitaxel (Taxol) 3-hour infusion without G-CSF
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Paclitaxel (Taxol) 3-hour infusion with G-CSF
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Paclitaxel (Taxol) 3-hour infusion
Number of subjects: 35
Study: 2895993

Group type: EXPERIMENTAL
Intervention: Clorazepate dipotassium (15 to 60 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Buspirone hydrochloride (10 to 40 mg/d)
Number of subjects: 0
Study: 31628668

Group type: EXPERIMENTAL
Intervention: Rifampicin 150 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Rifampicin 300 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Probe drug cocktail (atorvastatin, pitavastatin, rosuvastatin, valsartan)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nonlinear regression analysis
Number of subjects: 8
Study: 31078149

Group type: EXPERIMENTAL
Intervention: Humic acid (100 mg.L‐1) with CuO nanoparticles (various concentrations)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CuO nanoparticles (various concentrations) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Humic acid (100 mg.L‐1)
Number of subjects: 0
Study: 28327379

Group type: EXPERIMENTAL
Intervention: Computer tablet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telephone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 0
Study: 25288262

Group type: EXPERIMENTAL
Intervention: 2,790-nm resurfacing laser (double pass treatment at fluences less than or equal to 2.5 mJ with 10% overlap)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2,790-nm resurfacing laser (one pass treatment at fluences greater than or equal to 3.0 mJ with 10% overlap)
Number of subjects: 12
Study: 23982575

Group type: EXPERIMENTAL
Intervention: Pelvic floor physical therapy (PFPT) 2 weeks preoperatively and 2, 4, 6, 8, and 12 weeks postoperatively
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (standard care with physician assessment only)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pelvic floor physical therapy (PFPT)
Number of subjects: 49
Study: 21762357

Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg/Amlodipine 5 mg (T40/A5)
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg/Amlodipine 5 mg (T80/A5)
Number of subjects: 1097

Group type: COMPARATOR
Intervention: Amlodipine 5 mg (A5)
Number of subjects: 1097

Group type: COMPARATOR
Intervention: Amlodipine 10 mg (A10)
Number of subjects: 1097
Study: 19092234

Group type: EXPERIMENTAL
Intervention: NPPV plus usual dosage of oxygen
Number of subjects: 11

Group type: COMPARATOR
Intervention: NPPV
Number of subjects: 11

Group type: COMPARATOR
Intervention: Usual dosage of oxygen
Number of subjects: 11
Study: 16934402

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 123

Group type: COMPARATOR
Intervention: TENS-placebo
Number of subjects: 123
Study: 14574511

Group type: EXPERIMENTAL
Intervention: Scintigraphic evaluation using 5, 10, 15, and 20 ml of water containing 0.5 mCi technetium‐99m labelled sulphur colloid
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Electromyography (EMG) and laryngeal sensor monitoring (LS)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Scintigraphic evaluation
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Static thoracic images
Number of subjects: 34

Group type: COMPARATOR
Intervention: Normal adults (control group)
Number of subjects: 34
Study: 10818025

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 3685
Study: 8784560

Group type: EXPERIMENTAL
Intervention: PCR test for detection of meningococcal DNA in blood samples
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: PCR test for detection of meningococcal DNA in serum samples
Number of subjects: 80

Group type: COMPARATOR
Intervention: Prior antibiotic treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional techniques for diagnosing meningococcal disease
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Widespread application of the PCR test
Number of subjects: 80
Study: 1472394

Group type: EXPERIMENTAL
Intervention: Intervention group received immediate feedback on cholesterol concentration.
Number of subjects: 578

Group type: COMPARATOR
Intervention: Control group did not receive feedback on cholesterol concentration.
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Intervention group with initial cholesterol level of 6.50 mmol l‐1 or greater.
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Intervention group with initial cholesterol level of less than 5.20 mmol l‐1.
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Proportion of smokers not smoking at follow up in intervention group.
Number of subjects: 578

Group type: COMPARATOR
Intervention: Proportion of smokers not smoking at follow up in control group.
Number of subjects: 578
Study: 6143195

Group type: EXPERIMENTAL
Intervention: Hospice care
Number of subjects: 247

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 247
Study: 31505907

Group type: EXPERIMENTAL
Intervention: 10-day concomitant therapy (CT)
Number of subjects: 1141
Study: 28741030

Group type: EXPERIMENTAL
Intervention: MIS‐TLIF
Number of subjects: 41

Group type: COMPARATOR
Intervention: open TLIF
Number of subjects: 41
Study: 26437712

Group type: EXPERIMENTAL
Intervention: MenACWY-TT
Number of subjects: 500

Group type: COMPARATOR
Intervention: MenACWY-PS
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 500
Study: 24279296

Group type: EXPERIMENTAL
Intervention: Chest X-ray imaging offered to higher-risk patients with chest symptoms
Number of subjects: 0

Group type: COMPARATOR
Intervention: NICE guidelines for urgent referral for chest X-ray
Number of subjects: 0
Study: 21288514

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting covered metal stents (PECMSs)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Covered metal stents (CCMSs)
Number of subjects: 49
Study: 19701237

Group type: EXPERIMENTAL
Intervention: 250 mg clarithromycin tablets twice a day for 4 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo twice daily for 4 days
Number of subjects: 24
Study: 17590156

Group type: EXPERIMENTAL
Intervention: Sub-antimicrobial dose doxycycline (SDD)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 14981005

Group type: EXPERIMENTAL
Intervention: Stenting of both branches (group A)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Stenting of the main branch with provisional stenting of the side branch (group B)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Overall
Number of subjects: 85
Study: 11800243

Group type: EXPERIMENTAL
Intervention: Peer support group (conventional care plus telephone-based support initiated within 48 hours after hospital discharge)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Peer support group
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control group (conventional care)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 256
Study: 10412726

Group type: EXPERIMENTAL
Intervention: Lipopheresis using the Kaneka Liposorber system
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lipopheresis
Number of subjects: 20
Study: 8575574

Group type: EXPERIMENTAL
Intervention: Salmeterol 100 micrograms b.i.d. (n = 55)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo (n = 64)
Number of subjects: 119
Study: 1663856

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 0
Study: 7032811

Group type: EXPERIMENTAL
Intervention: Low-salt diet
Number of subjects: 3

Group type: COMPARATOR
Intervention: Free sodium diet
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Acute salt loading
Number of subjects: 3
Study: 6704545

Group type: COMPARATOR
Intervention: Maintenance therapy with weekly cytosine arabinoside and 6‐thioguanine alone (69 patients)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Two courses of reduced doses of DAT 1 month apart followed by the same maintenance program (77 patients)
Number of subjects: 283
Study: 26752653

Group type: EXPERIMENTAL
Intervention: High dose clazosentan (15 mg/h)
Number of subjects: 2159
Study: 27558580

Group type: EXPERIMENTAL
Intervention: 100-kcal portions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 600-kcal portions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Scenario 1 (Study 2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Scenario 2 (Study 2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Scenario 3 (Study 2)
Number of subjects: 24
Study: 24794369

Group type: EXPERIMENTAL
Intervention: Tdap vaccination during pregnancy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 22835570

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) applied twice on the cervical erosion with a 1-week interval
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nd-YAG laser used once for tissue vaporization
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nd-YAG laser
Number of subjects: 120
Study: 20420610

Group type: EXPERIMENTAL
Intervention: Low-resistance, high-compliant oxygenator (Quadrox BE-HMO 2000)
Number of subjects: 40

Group type: COMPARATOR
Intervention: High-resistance, low-compliant oxygenator (Capiox SX18)
Number of subjects: 40
Study: 18686348

Group type: EXPERIMENTAL
Intervention: Kiwi Omnicup (KO)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Malmstrom metal cup (MM)
Number of subjects: 164
Study: 15878730

Group type: EXPERIMENTAL
Intervention: Eyeblink conditioning in patients with schizophrenia
Number of subjects: 13

Group type: COMPARATOR
Intervention: Eyeblink conditioning in controls
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Timing of responses in patients with schizophrenia
Number of subjects: 13

Group type: COMPARATOR
Intervention: Timing of responses in controls
Number of subjects: 13
Study: 12671149

Group type: EXPERIMENTAL
Intervention: Indomethacin plus IVH
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Indomethacin no IVH
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Saline plus IVH
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Saline with no IVH
Number of subjects: 328
Study: 10641420

Group type: EXPERIMENTAL
Intervention: Apranax
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cataflam
Number of subjects: 0
Study: 8911108

Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy (VIMP) - vincristine, carboplatin, ifosfamide, mesna
Number of subjects: 143

Group type: COMPARATOR
Intervention: Standard chemotherapy (CDE) - cyclophosphamide, doxorubicin, etoposide
Number of subjects: 143
Study: 1651434

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (one injection daily)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Combination of low molecular weight heparin + dihydroergotamine (one injection daily)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (3 applications of 5000 IU per day)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (Low molecular weight heparin alone)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (Combination treatment)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (Unfractionated heparin)
Number of subjects: 105
Study: 6854869

Group type: EXPERIMENTAL
Intervention: Mailed periodic reprints (group 1)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Quarterly patient management problems (group 2)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 132
Study: 31883516

Group type: EXPERIMENTAL
Intervention: uPOD+PT
Number of subjects: 95

Group type: COMPARATOR
Intervention: uPOD
Number of subjects: 95
Study: 29391292

Group type: EXPERIMENTAL
Intervention: Video tutorial group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (slide show)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Video tutorial group (second simulation session)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Video tutorial group (first simulation session)
Number of subjects: 0
Study: 26541888

Group type: EXPERIMENTAL
Intervention: Encapsulated ileal-release glutamine (6.0 g)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 23661494

Group type: EXPERIMENTAL
Intervention: 8-week preoperative neuromuscular supervised exercise programme delivered twice a week for 1 hour as adjunct treatment to standard arthroplasty procedure
Number of subjects: 165

Group type: COMPARATOR
Intervention: Standard arthroplasty procedure alone
Number of subjects: 165
Study: 21678172

Group type: EXPERIMENTAL
Intervention: Distance to snacks at 20 cm (proximal condition)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Distance to snacks at 70 cm
Number of subjects: 131

Group type: COMPARATOR
Intervention: Distance to snacks at 140 cm
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Self-report ratings of salience and effort in Study 2
Number of subjects: 131
Study: 21110409

Group type: EXPERIMENTAL
Intervention: High-dosage (HD) medical exercise therapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Low-dosage (LD) exercise therapy
Number of subjects: 61
Study: 17956016

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray 200 g twice-daily (b.i.d.)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray 200 g once-daily (q.d.)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 mg three times daily (t.i.d.)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study: 15875135

Group type: EXPERIMENTAL
Intervention: N2O administration during washout of sevoflurane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (sevoflurane and N2O discontinued immediately after surgery)
Number of subjects: 20
Study: 12584874

Group type: COMPARATOR
Intervention: Nicotine patch (NTP; n = 27)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Bupropion SR (B; n = 101)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Bupropion SR plus nicotine patch (B + NTP; n = 61)
Number of subjects: 189
Study: 10921056

Group type: EXPERIMENTAL
Intervention: Radiotherapy (40 Gy) followed by surgery (R + S)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Surgery alone (S)
Number of subjects: 201
Study: 7978436

Group type: COMPARATOR
Intervention: 0.25 mg triazolam orally (Group 1)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 75 micrograms oral clonidine (Group 2)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 150 micrograms oral clonidine (Group 3)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 300 micrograms oral clonidine (Group 4)
Number of subjects: 47
Study: 3140861

Group type: EXPERIMENTAL
Intervention: 100% oxygen supplemented by 1.5 x MAC of halothane
Number of subjects: 40

Group type: COMPARATOR
Intervention: 50% nitrous oxide, and 0.5% halothane (group 1, controls)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 100% oxygen supplemented by 1.5 x MAC of enflurane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 100% oxygen supplemented by 1.5 x MAC of isoflurane
Number of subjects: 40
Study: 4407085

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin
Number of subjects: 132

Group type: COMPARATOR
Intervention: Intravenous dextran 70
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Both treatments (Subcutaneous heparin and Intravenous dextran 70)
Number of subjects: 132
Study: 31449685

Group type: EXPERIMENTAL
Intervention: Concomitant antiplatelet therapy (APT)
Number of subjects: 2361

Group type: COMPARATOR
Intervention: No concomitant antiplatelet therapy (Control group)
Number of subjects: 2361
Study: 28534153

Group type: COMPARATOR
Intervention: Bevacizumab monotherapy
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus carboplatin
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Both arms (Bevacizumab monotherapy and Bevacizumab plus carboplatin)
Number of subjects: 122
Study: 26377550

Group type: EXPERIMENTAL
Intervention: Advanced pelvic floor exercise program (Pfilates and Hypopressives) for 26 weeks
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional pelvic floor exercises for 26 weeks
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Advanced pelvic floor exercise program (Pfilates and Hypopressives)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional pelvic floor exercises
Number of subjects: 88
Study: 23416308

Group type: EXPERIMENTAL
Intervention: GS-9620 (0.3, 1, 2, 4, 6, 8 or 12 mg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: GS-9620 (8 or 12 mg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: GS-9620 (≥ 2 mg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 21135022

Group type: EXPERIMENTAL
Intervention: ABT‐874 200 mg every other week (EOW)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: ABT‐874 200 mg every week (EW)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 19440081

Group type: EXPERIMENTAL
Intervention: lamotrigine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: divalproex sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 17234425

Group type: EXPERIMENTAL
Intervention: Blake 24F drain
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Jostra 32F silastic drain
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Argyle 32F plastic drain
Number of subjects: 150

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 150
Study: 15329205

Group type: EXPERIMENTAL
Intervention: Cpd 861
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 11347832

Group type: EXPERIMENTAL
Intervention: Osteoarthritis group (49 knees)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (13 knees)
Number of subjects: 32
Study: 10950467

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Phenelzine
Number of subjects: 43
Study: 8515823

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (EGb 761, Tebonin)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3461725

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg + codeine 16 mg + caffeine 30 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 31886591

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention (two consultations with a pharmacist 1-2 and 3-5 weeks after filling the prescription)
Number of subjects: 1480

Group type: EXPERIMENTAL
Intervention: Statin users in the intervention group
Number of subjects: 1480

Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 1480

Group type: COMPARATOR
Intervention: New statin users in the general population
Number of subjects: 1480
Study: 29437940

Group type: EXPERIMENTAL
Intervention: Standard LTBI treatment plus two-way weekly text messaging
Number of subjects: 358

Group type: COMPARATOR
Intervention: Standard LTBI treatment
Number of subjects: 358
Study: 26446245

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal system
Number of subjects: 0